Effects of gender and socio-environmental factors on health-care access in oncology: a comprehensive, nationwide study in France.

Gender Health-care access Oncology Socio-environmental factors

Journal

EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 26 06 2023
revised: 12 10 2023
accepted: 13 10 2023
medline: 15 11 2023
pubmed: 15 11 2023
entrez: 15 11 2023
Statut: epublish

Résumé

Gender-based disparities in health-care are common and can affect access to care. We aimed to investigate the impact of gender and socio-environmental indicators on health-care access in oncology in France. Using the national health insurance system database in France, we identified patients (aged ≥18 years) who were diagnosed with solid invasive cancers between the 1st of January 2018 and the 31st of December 2019. We ensured that only incident cases were identified by excluding patients with an existing cancer diagnosis in 2016 and 2017; skin cancers other than melanoma were also excluded. We extracted 71 socio-environmental variables related to patients' living environment and divided these into eight categories: inaccessibility to public transport, economic deprivation, unemployment, gender-related wage disparities, social isolation, educational barriers, familial hardship, and insecurity. We employed a mixed linear regression model to assess the influence of age, comorbidities, and all eight socio-environmental indices on health-care access, while evaluating the interaction with gender. Health-care access was measured using absolute and relative cancer care expertise indexes. In total, 594,372 patients were included: 290,658 (49%) women and 303,714 (51%) men. With the exception of unemployment, all socio-environmental indices, age, and comorbidities were inversely correlated with health-care access. However, notable interactions with gender were observed, with a stronger association between socio-environmental factors and health-care access in women than in men. In particular, inaccessibility to public transport (coefficient for absolute cancer care expertise index = -1.10 [-1.22, -0.99], p < 0.0001), familial hardship (-0.64 [-0.72, -0.55], p < 0.0001), social isolation (-0.38 [-0.46, -0.30], p < 0.0001), insecurity (-0.29 [-0.37, -0.21], p < 0.0001), and economic deprivation (-0.13 [-0.19, -0.07], p < 0.0001) had a strong negative impact on health-care access in women. Access to cancer care is determined by a complex interplay of gender and various socio-environmental factors. While gender is a significant component, it operates within the context of multiple socio-environmental influences. Future work should focus on developing targeted interventions to address these multifaceted barriers and promote equitable health-care access for both genders. None.

Sections du résumé

Background UNASSIGNED
Gender-based disparities in health-care are common and can affect access to care. We aimed to investigate the impact of gender and socio-environmental indicators on health-care access in oncology in France.
Methods UNASSIGNED
Using the national health insurance system database in France, we identified patients (aged ≥18 years) who were diagnosed with solid invasive cancers between the 1st of January 2018 and the 31st of December 2019. We ensured that only incident cases were identified by excluding patients with an existing cancer diagnosis in 2016 and 2017; skin cancers other than melanoma were also excluded. We extracted 71 socio-environmental variables related to patients' living environment and divided these into eight categories: inaccessibility to public transport, economic deprivation, unemployment, gender-related wage disparities, social isolation, educational barriers, familial hardship, and insecurity. We employed a mixed linear regression model to assess the influence of age, comorbidities, and all eight socio-environmental indices on health-care access, while evaluating the interaction with gender. Health-care access was measured using absolute and relative cancer care expertise indexes.
Findings UNASSIGNED
In total, 594,372 patients were included: 290,658 (49%) women and 303,714 (51%) men. With the exception of unemployment, all socio-environmental indices, age, and comorbidities were inversely correlated with health-care access. However, notable interactions with gender were observed, with a stronger association between socio-environmental factors and health-care access in women than in men. In particular, inaccessibility to public transport (coefficient for absolute cancer care expertise index = -1.10 [-1.22, -0.99], p < 0.0001), familial hardship (-0.64 [-0.72, -0.55], p < 0.0001), social isolation (-0.38 [-0.46, -0.30], p < 0.0001), insecurity (-0.29 [-0.37, -0.21], p < 0.0001), and economic deprivation (-0.13 [-0.19, -0.07], p < 0.0001) had a strong negative impact on health-care access in women.
Interpretation UNASSIGNED
Access to cancer care is determined by a complex interplay of gender and various socio-environmental factors. While gender is a significant component, it operates within the context of multiple socio-environmental influences. Future work should focus on developing targeted interventions to address these multifaceted barriers and promote equitable health-care access for both genders.
Funding UNASSIGNED
None.

Identifiants

pubmed: 37965434
doi: 10.1016/j.eclinm.2023.102298
pii: S2589-5370(23)00475-3
pmc: PMC10641482
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102298

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

We declare no competing interests.

Références

Cancer. 2005 Feb 1;103(3):483-91
pubmed: 15597407
J Cancer Res Clin Oncol. 2020 May;146(5):1169-1196
pubmed: 32246217
Dis Colon Rectum. 2009 Dec;52(12):1982-91
pubmed: 19959975
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5797-801
pubmed: 23530191
BMC Public Health. 2019 Jan 16;19(1):74
pubmed: 30651092
Res Integr Peer Rev. 2016 May 03;1:2
pubmed: 29451543
MMWR Surveill Summ. 2017 Jul 07;66(14):1-13
pubmed: 28683054
Cancer. 2019 Sep 1;125(17):3033-3039
pubmed: 31090932
Br J Surg. 2014 Jul;101(8):1000-5
pubmed: 24844590
Future Healthc J. 2022 Jul;9(2):101-105
pubmed: 35928198
Cancer. 2016 Jul 1;122(13):2012-20
pubmed: 27224661
Lancet Reg Health Eur. 2022 Nov 28;25:100551
pubmed: 36818237
Ann Epidemiol. 2020 Jun;46:14-19
pubmed: 32532368
Br J Surg. 2013 Jan;100(1):83-94
pubmed: 23180474
J Natl Compr Canc Netw. 2021 Feb 9;19(5):495-503
pubmed: 33561825
Arch Gynecol Obstet. 2019 Feb;299(2):299-315
pubmed: 30542793
Eur J Cancer. 2011 Nov;47(17):2493-511
pubmed: 22033323
BMC Public Health. 2012 Mar 19;12:201
pubmed: 22429338
CA Cancer J Clin. 2016 Jul;66(4):337-50
pubmed: 26891458
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cancer Surviv. 2023 Dec;17(6):1571-1582
pubmed: 35579665
Gynecol Oncol. 2010 Sep;118(3):262-7
pubmed: 20573392
Nat Rev Clin Oncol. 2019 Dec;16(12):746-761
pubmed: 31350467
Int J Environ Res Public Health. 2020 Dec 08;17(24):
pubmed: 33302577
Lancet Oncol. 2012 Apr;13(4):353-65
pubmed: 22365494
Semin Radiat Oncol. 2012 Oct;22(4):265-71
pubmed: 22985808
Trends Cancer. 2021 Jun;7(6):488-495
pubmed: 33446449
Behav Sci (Basel). 2020 May 26;10(6):
pubmed: 32466504
Gynecol Oncol. 2014 Feb;132(2):403-10
pubmed: 24361578
JAMA Netw Open. 2022 Feb 1;5(2):e2146461
pubmed: 35107574
JAMA. 2004 Mar 10;291(10):1238-45
pubmed: 15010446
BMC Public Health. 2017 May 10;17(1):422
pubmed: 28486983
Br J Cancer. 2022 Mar;126(4):652-663
pubmed: 34741134
Cancer. 2014 Feb 15;120(4):555-61
pubmed: 24496869
Environ Health. 2011 Apr 05;10 Suppl 1:S7
pubmed: 21489217
ESMO Open. 2020 Aug;5(Suppl 4):e000773
pubmed: 32816862

Auteurs

Floriane Jochum (F)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Department of Gynecology, Strasbourg University Hospital, Strasbourg, France.

Anne-Sophie Hamy (AS)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Department of Medical Oncology, Institut Curie, Paris, France.

Paul Gougis (P)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Élise Dumas (É)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Beatriz Grandal (B)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Enora Laas (E)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Jean-Guillaume Feron (JG)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Thomas Gaillard (T)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Noemie Girard (N)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Lea Pauly (L)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Elodie Gauroy (E)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Lauren Darrigues (L)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Judicael Hotton (J)

Department of Surgical Oncology, Institut Godinot, Reims, France.

Lise Lecointre (L)

Department of Gynecology, Strasbourg University Hospital, Strasbourg, France.

Fabien Reyal (F)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Cherif Akladios (C)

Department of Gynecology, Strasbourg University Hospital, Strasbourg, France.

Fabrice Lecuru (F)

Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.

Classifications MeSH